ASH 2023: Anticipating Impactful Data in DLBCL

Suchitra Sundaram, MD

December 01, 2023

Suchitra Sundaram, MD, discusses several exciting studies to be presented in diffuse large B-cell lymphoma (DLBCL) at this year's ASH conference, including the Smart Stop trial assessing lenalidomide, rituximab, tafasitamab, and acalabrutinib as initial therapy to potentially reduce chemoimmunotherapy cycles.

Additionally, Dr Sundaram previews a study that explores mosunetuzumab and polatuzumab in older patients with DLBCL and another trial that investigates glofitamab with R-CHOP, using ctDNA as a biomarker. Notably, trials like ELM-2, with odronextamab in relapsed DLBCL, and one on a five-drug combination in refractory DLBCL, bring promise to the field.

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: ASH 2023: Anticipating Impactful Data in DLBCL - Medscape - Dec 01, 2023.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.